Inhibition of the autocrine IL-6–JAK2–STAT3–calprotectin axis as targeted therapy for HR−/HER2+breast cancers
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
HER2-positive (HER2+) breast adenocarcinomas are a heterogeneous group in which hormone receptor (HR) status influences therapeutic decisions and patient outcome. By combining genome-wide RNAi screens with regulatory network analysis, we identified STAT3 as a critically activated master regulator of HR−/HER2+tumors, eliciting tumor dependency in these cells. Mechanistically, HR−/HER2+cells secrete high levels of the interleukin-6 (IL-6) cytokine, inducing the activation of STAT3, which in turn promotes a second autocrine stimulus to increase S100A8/9 complex (calprotectin) production and secretion. Increased calprotectin levels activate signaling pathways involved in proliferation and resistance. Importantly, we demonstrated that inhibition of the IL-6–Janus kinase 2 (JAK2)–STAT3–calprotectin axis with FDA-approved drugs, alone and in combination with HER2 inhibitors, reduced the tumorigenicity of HR−/HER2+breast cancers, opening novel targeted therapeutic opportunities.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
METABRIC Group, Curtis, C., Shah, S. P., Chin, S.-F., Turashvili, G., Rueda, O. M., Dunning, M. J., Speed, D., Lynch, A. G., Samarajiwa, S., et al. (2012) · Nature · doi:10.1038/nature10983 · Cited by 6,097
The JAK/STAT signaling pathway
Rawlings, J. S., Rosler, K. M., & Harrison, D. A. (2004) · Journal of Cell Science · doi:10.1242/jcs.00963 · Cited by 1,858
The JAK-STAT Signaling Pathway: Input and Output Integration
Murray, P. J. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.5.2623 · Cited by 1,179
A CXCL1 Paracrine Network Links Cancer Chemoresistance and Metastasis
Acharyya, S., Oskarsson, T., Vanharanta, S., Malladi, S., Kim, J., Morris, P. G., Manova-Todorova, K., Leversha, M., Hogg, N., Seshan, V. E., et al. (2012) · Cell · doi:10.1016/j.cell.2012.04.042 · Cited by 1,085 · cited 2×
“Exposure to S100A8/9 has been shown to activate canonical signal transduction pathways that are involved in tumorigenesis by increasing proliferation, resistance to stress, and protein synthesis (Gebhardt et al. 2006; Hermani et al. 2006; Ichikawa et al. 2011; Acharyya et al. 2012).”
BackgroundS100A8 and S100A9 in inflammation and cancer
Gebhardt, C., Németh, J., Angel, P., & Hess, J. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2006.05.017 · Cited by 696 · cited 5×
“S100A8 and S100A9 are calcium-binding proteins that heterodimerize, forming a complex called calprotectin that is secreted (Gebhardt et al. 2006; Ehrchen et al. 2009).”
BackgroundResultInfluentialThe IL-6/JAK/Stat3 feed-forward loop drives tumorigenesis and metastasis
Chang, Q., Bournazou, E., Sansone, P., Berishaj, M., Gao, S. P., Daly, L., Wels, J., Theilen, T., Granitto, S., Zhang, X., et al. (2013) · Neoplasia · doi:10.1593/neo.13706 · Cited by 494
Inhibitors of Cytokine Signal Transduction
Wormald, S., & Hilton, D. J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.r300030200 · Cited by 440
S100A8/A9 activate key genes and pathways in colon tumor progression
Ichikawa, M., Williams, R., Wang, L., Vogl, T., & Srikrishna, G. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0394 · Cited by 346 · cited 2×
“Exposure to S100A8/9 has been shown to activate canonical signal transduction pathways that are involved in tumorigenesis by increasing proliferation, resistance to stress, and protein synthesis (Gebhardt et al. 2006; Hermani et al. 2006; Ichikawa et al. 2011; Acharyya et al. 2012).”
BackgroundValidating Stat3 in cancer therapy
Darnell, J. E. (2005) · Nature Medicine · doi:10.1038/nm0605-595 · Cited by 307 · cited 2×
“In addition, MCF-10A/ErbB2∗ cells were injected in triplicate into the intramammary fat pad (IMFP) of immunocompromised mice to perform the in vivo screening. Experimental details are described in Rodriguez-Barrueco et al. (2013). Data analysis details are described in Yu et al.”
BackgroundMethodHurley, J., Doliny, P., Reis, I., Silva, O., Gomez-Fernandez, C., Velez, P., Pauletti, G., Powell, J. E., Pegram, M. D., & Slamon, D. J. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.8886 · Cited by 245
Cited by
Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer
Xue, C., Yao, Q., Gu, X., Shi, Q., Yuan, X., Chu, Q., Bao, Z., Lu, J., & Li, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01468-7 · Cited by 699
The role of IL-6/JAK2/STAT3 signaling pathway in cancers
Huang, B., Lang, X., & Li, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1023177 · Cited by 479
IL-6/JAK/STAT3 Signaling in Breast Cancer Metastasis: Biology and Treatment
Manore, S. G., Doheny, D. L., Wong, G. L., & Lo, H.-W. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.866014 · Cited by 307
Alvarez, M. J., Subramaniam, P. S., Tang, L. H., Grunn, A., Aburi, M., Rieckhof, G., Komissarova, E. V., Hagan, E. A., Bodei, L., Clemons, P. A., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0138-4 · Cited by 210
Self-citationChen, Y., Ouyang, Y., Li, Z., Wang, X., & Ma, J. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188891 · Cited by 165
Metadata
- Authors
- Rodriguez-Barrueco, R., Yu, J., Saucedo-Cuevas, L. P., Olivan, M., Llobet-Navas, D., Putcha, P., Castro, V., Murga-Penas, E. M., Collazo-Lorduy, A., Castillo-Martin, M., Alvarez, M., Cordon-Cardo, C., Kalinsky, K., Maurer, M., Califano, A., & Silva, J. M.
- Venue
- Genes & Development
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2015-07-30
- Volume
- 29
- Issue
- 15
- Pages
- 1631-1648
- ISSN
- 0890-9369 (ISSN-L)
- 1549-5477
- OpenAlex
- W2158357903
- Cited by
- 110
- References
- 13
- Type
- posted content
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Inhibition of the autocrine IL-6–JAK2–STAT3–calprotectin axis as targeted therapy for HR−/HER2+breast cancers. https://app.cochat.ai/papers/10.1101/gad.262642.115
- The paper
- Rodriguez-Barrueco, R., Yu, J., Saucedo-Cuevas, L. P., Olivan, M., Llobet-Navas, D., Putcha, P., Castro, V., Murga-Penas, E. M., Collazo-Lorduy, A., Castillo-Martin, M., Alvarez, M., Cordon-Cardo, C., Kalinsky, K., Maurer, M., Califano, A., & Silva, J. M. (2015). Inhibition of the autocrine IL-6–JAK2–STAT3–calprotectin axis as targeted therapy for HR−/HER2+breast cancers. Genes & Development. https://doi.org/10.1101/gad.262642.115
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.